MRSA-I Print E-mail

Welcome to the MRSA Initiative

Addressing the challenges in the management and treatment of Methicillin-Resistant Staphylococcus Aureus

In considering the overall issue of Methicillin-resistant Staphylococcus aureus (MRSA) within North America and around the world, the American Society for Microbiology (ASM) has carefully noted the segments within the overall issue where additional/new information would serve to improve the overall understanding of MRSA and its true impact on patients, the medical community and society in general. Understanding that local, regional and national resources for addressing MRSA can vary around the globe, the ASM is focused on presenting a range of options within each key element of the MRSA Initiative (MRSA-I).  

This program has been established to focus on the complex and critical issues related to MRSA facing the medical community and the population as a whole. The structure and content of this initiative has been developed based on the needs assessment data compiled by the ASM, corroborated via the program faculty and additional supporting research.

MRSA has emerged as a cause of skin infections and, less commonly, invasive infections among otherwise healthy adults and children in the community. More data are needed in order to fully understand the epidemiology, microbiology, and pathophysiology of these infections and to identify optimal prevention and treatment strategies.1

Multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and certain gram-negative bacilli (GNB) have important infection control implications that either have not been addressed or received only limited consideration in isolation guidelines. Although transmission of MDROs is most frequently documented in acute care facilities, all healthcare settings are affected by the emergence and transmission of antimicrobial-resistant microbes.

The severity and extent of disease caused by these pathogens varies by the population(s) affected and by the institution(s) in which they are found. Institutions, in turn, vary widely in physical and functional characteristics, ranging from long-term care facilities (LTCF) to specialty units (e.g., intensive care units [ICU], burn units, neonatal ICUs [NICUs]) in tertiary care facilities. Because of this, the approaches to prevention and control of these pathogens need to be tailored to the specific needs of each population and individual institution.2


2 Siegel et al, Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006, CDC publication


Organized by:
MRSA Initiative
ASM wishes to recognize Astellas Pharma, US, Inc., for providing an educational grant to support MRSA-I